Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Geographic Atrophy: Expanding Our Understanding of the Disease and its Management

By: Rishi P. Singh, MD; Nathan Steinle, MD; Charles C. Wykoff, MD, PhD

Webinar Credits: 1.25

Geographic atrophy (GA) is an advanced form of age-related macular degeneration for which there is currently no treatment approved by the US FDA. This webinar will review in-depth the latest information on GA, including the investigative therapies showing positive outcomes in clinical trials. The expert faculty will also share their expertise related to the optimal imaging modalities for evaluating GA and share case studies for discussion.

Expiration Date: Thursday, September 30, 2021
Release Date: September 14th, 2020

Learning Objectives

  • Describe the prevalence of AMD and classify by severity: early, intermediate, and advanced (ie, wet AMD and GA)
  • Explain the pathogenesis of GA
  • Distinguish which imaging modalities are best suited for GA evaluation
  • Categorize new therapies in the pipeline for GA
  • Evaluate the functional and anatomic outcomes used in managing patients with GA

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

 

Course Viewing Requirements

Supported Browsers:

Internet Explorer 11 for Windows

Edge (recent versions; Chromium-based) for Windows

Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:

4GB+ RAM

Recommended internet speed 5Mbps+

 

Faculty and Disclosures

Faculty:

Rishi P. Singh, MD
Staff Physician
Cole Eye Institute
Associate Professor of Ophthalmology
Cleveland Clinic
Lerner College of Medicine
Cleveland, Ohio

Nathan Steinle, MD 
California Retina Consultants
Santa Barbara, CA

Charles C. Wykoff, MD, PhD
Retina Consultants of Houston
Houston Methodist Hospital
Blanton Eye Institute
Houston, Texas

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Rishi P. Singh, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Bausch + Lomb, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Apellis and Graybug.

Nathan Steinle, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech, Novartis and Regeneron Pharmaceuticals; Grant/Research Support: Genentech, Novartis and Regeneron Pharmaceuticals. Speaker’s Bureau: Genentech, Novartis and Regeneron Pharmaceuticals.

Charles C. Wykoff, MD, PhD, FACS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera, Allergan, Genentech, Novartis, and Regeneron. Grant/Research Support: Allergan, Genentech, Novartis, and Regeneron. Speaker’s Bureau: Regeneron.

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis.

Video Resources

BackNext

Test

Instructions

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Step 1 of 2

  • 1. Not at all confident2. Not very confident3. Neutral4. Confident5. Extremely confident
  • AgreeNeutralDisagree
    Describe the prevalence of AMD and classify by severity: early, intermediate, and advanced (ie, wet AMD and GA)
    Explain the pathogenesis of GA
    Distinguish which imaging modalities are best suited for GA evaluation
    Categorize new therapies in the pipeline for GA
    Evaluate the functional and anatomic outcomes used in managing patients with GA
Back